title: [Effect of CIK on long-term survival in the treatment of HCC after RFA combined TACE].
abstract: OBJECTIVE
  To evaluate the clinical effects of autologous cytokine-induced killer cell(CIK) on the cumulative survival and reactivation rate of hepatitics B virus(HBV) after radiofrequency ablation(RFA) combined with transcatheter arterial chemoembolization(TACE).
  
  
  METHODS
  A total of 156 patients with hepatocellular carcinoma treated from June 2006 to September 2012 in Shengli Oilfield Central Hosptial were divided into control group(RFA, TACE) and research group(RFA, TACE, CIK). According to the tumors number, diameter and vascular invasion condition, the patients were divided into another 4 groups: the high and low risk group with tumor ≤5 cm, the high and low risk group with tumor>5 cm.The prognosis of these groups was analyzed. The effects on HBV reactivation rate between antiviral and unantiviral patients were respectively analyzed .
  
  
  RESULTS
  The ratios of the research and control group over 1-, 3-, 5-year were 75.3%(70/93), 58.9%(53/90), 21.5%(20/93)vs 71.4%(45/63), 55.6%(35/63), 22.2%(14/63)(P>0.05), the ratios of the research and control group in the high risk group with tumor≤5 cm were 75.0%(18/24), 58.3%(14/24), 37.5%(9/24)vs 58.8%(10/17), 41.2%(7/17), 23.5%(4/17)(P<0.05). The incidences of HBV reactivation for the research and control group were 6.0% and 24.3%(P<0.05).
  
  
  CONCLUSIONS
  Postoperative adjuvant CIK therapy with tumor≤5 cm after RFA combined with TACE is beneficial to the high risk group and decreases the risk of HBV reactivation.
authors.affiliation: Department of Hepatobiliary Surgery , Shengli Oilfield Central Hospital, Dongying 257034, China.
authors.forename: G Z
authors.initials: GZ
authors.lastname: Pan
authors.forename: J B
authors.initials: JB
authors.lastname: Xu
authors.forename: L
authors.initials: L
authors.lastname: Hao
authors.forename: J
authors.initials: J
authors.lastname: Zhang
authors.forename: S L
authors.initials: SL
authors.lastname: Li
authors.forename: Q Z
authors.initials: QZ
authors.lastname: Yuan
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000628:therapy* / Q000821:virology; D017115:Catheter Ablation; D064987:Cell- and Tissue-Based Therapy; D016461:Chemoembolization, Therapeutic; D003131:Combined Modality Therapy; D055612:Cytokine-Induced Killer Cells / Q000166:cytology*; D006509:Hepatitis B / Q000628:therapy; D006515:Hepatitis B virus; D006801:Humans; D008113:Liver Neoplasms / Q000628:therapy* / Q000821:virology; D011379:Prognosis